2017
DOI: 10.1016/j.bbr.2016.08.053
|View full text |Cite
|
Sign up to set email alerts
|

Neurobehavioral deficits in the KIKO mouse model of Friedreich’s ataxia

Abstract: Friedreich’s Ataxia (FA) is a pediatric neurodegenerative disease whose clinical presentation includes ataxia, muscle weakness, and peripheral sensory neuropathy. The KIKO mouse is an animal model of FA with frataxin deficiency first described in 2002, but neurobehavioral deficits have never been described in this model. The identification of robust neurobehavioral deficits in KIKO mice could support the testing of drugs for FA, which currently has no approved therapy. We tested 13 neurobehavioral tasks to ide… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
22
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(25 citation statements)
references
References 35 publications
2
22
0
Order By: Relevance
“…We first examined the levels of frataxin and the mitochondrial biogenesis master regulator PGC-1α in cerebellar homogenates of KIKO mice at both asymptomatic [postnatal day (P) 30, P90, P180] and symptomatic (P270) ages ( McMackin et al, 2016 ). In wild-type control mice, frataxin and PGC-1α levels are slightly decreased or remain unaltered in cerebellar homogenates at P180 and P270 compared with P30 and P90 ( …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We first examined the levels of frataxin and the mitochondrial biogenesis master regulator PGC-1α in cerebellar homogenates of KIKO mice at both asymptomatic [postnatal day (P) 30, P90, P180] and symptomatic (P270) ages ( McMackin et al, 2016 ). In wild-type control mice, frataxin and PGC-1α levels are slightly decreased or remain unaltered in cerebellar homogenates at P180 and P270 compared with P30 and P90 ( …”
Section: Resultsmentioning
confidence: 99%
“…No overt neuronal loss appears in initial studies, but mRNA panels from tissue share many features with those from patients ( Miranda et al, 2002 ). More sophisticated studies in KIKO mice identify significant neurobehavioral deficits in inverted screen, treadscan and Von Frey tasks at >8 months of age, resembling clinical manifestations of cerebellar gait ataxia, decreased peripheral sensitivity, and decreased motor strength and endurance in late-onset FRDA patients ( McMackin et al, 2016 ). Thus, the KIKO mouse constitutes a suitable model to search for early pathophysiological changes of FRDA by examining its physiological and biochemical properties at asymptomatic ages (1, 3 and 6 months of age).…”
Section: Introductionmentioning
confidence: 99%
“…Herein, we used KIKO mouse that represents a suitable in vivo model for studying neurodegeneration as well as metabolic complications in FRDA 17,22 . We firstly monitored body weight and a trend to gain weight was observed in 6 months KIKO mice that becomes significant at 8 months of age (Fig.…”
Section: Alteration Of Basal Metabolic Parameters In Kiko Micementioning
confidence: 99%
“…No overt neuronal loss appears in initial studies but mRNA panels from tissue share many features with those from patients ( Miranda et al, 2002 ). Recent neurobehavioral studies in KIKO mice show cerebellar ataxia, decreased peripheral sensitivity, and decreased motor strength and endurance at 9 months of age, resembling clinical manifestations observed in late-onset FRDA patients ( McMackin et al, 2016 ). This phenotypically abnormal mouse with solid biochemical deficits, but no overt cell loss, thus provides a model to search for CNS abnormalities that mediate the earliest cerebellar features of FRDA.…”
Section: Introductionmentioning
confidence: 69%